Authors
Latest:
Mitigating Risk in Implementing Multi-Regional Trials in MSExamining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.
Latest:
Mitigating Risk in Implementing Multi-Regional Trials in MSExamining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.
Latest:
Mitigating Risk in Implementing Multi-Regional Trials in MSExamining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.
Latest:
Mitigating Risk in Implementing Multi-Regional Trials in MSExamining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.
Latest:
Mitigating Risk in Implementing Multi-Regional Trials in MSExamining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.
Latest:
Mitigating Risk in Implementing Multi-Regional Trials in MSExamining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.
Latest:
Mitigating Risk in Implementing Multi-Regional Trials in MSExamining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.
Latest:
Understanding the Investigator Usage of Individual Pharmaceutical Companies; the Pfizer CaseWith Open Payments it is possible for Pfizer to better understand its own investigator usage pattern and how that pattern may differ from the practices of other pharmaceutical companies.
Latest:
Clinical Trials in the Baltic StatesThe region has an appropriate population size, solid infrastructure, experienced nvestigators, and short timelines.
Latest:
Enrollment Cycle Times Can and Should Be OptimizedCase study shows that site activation is a key driver in determining patient enrollment cycle time, which can be minimized by identifying the "sweet spot" of sites to deploy for a clinical trial.
Latest:
A Digital Twin on CAR-T Cytokine Release Syndrome (CRS) Patients with Standard of Care Measured by CRS Distribution by GradeUsing existing clinical trial data to proactively model patient safety and efficacy outcomes could aid in accelerating development for areas in need of new therapies.
Latest:
Enrollment Cycle Times Can and Should Be OptimizedCase study shows that site activation is a key driver in determining patient enrollment cycle time, which can be minimized by identifying the "sweet spot" of sites to deploy for a clinical trial.
Latest:
Build Trust with Honesty and CommunicationThe importance of openness and loyalty cannot be overlooked when cultivating a parternship.
Latest:
Challenges Emerge from Low NASH AwarenessAddressing the current hurdles and potential solutions in nonalcoholic steatohepatitis awareness and clinical trial enrollment.
Latest:
Considering Sex as a Variable in Clinical TrialsA sex-bias that significantly impacts the advancement of women’s health exists in both preclinical and clinical research.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Value of Virtual Care Technology in Clinical TrialsVirtual care technology is emerging as a valuable tool for clinical trials, helping to improve recruiting and strengthen retention while optimizing resources for the overall study.
Latest:
Models of Engagement: Patients as Partners in Clinical ResearchExploring three distinct patient partnership models to help researchers assess which methods of engagement could work best for their clinical programs.
Latest:
Models of Engagement: Patients as Partners in Clinical ResearchExploring three distinct patient partnership models to help researchers assess which methods of engagement could work best for their clinical programs.
Latest:
Models of Engagement: Patients as Partners in Clinical ResearchExploring three distinct patient partnership models to help researchers assess which methods of engagement could work best for their clinical programs.
Latest:
Models of Engagement: Patients as Partners in Clinical ResearchExploring three distinct patient partnership models to help researchers assess which methods of engagement could work best for their clinical programs.
Latest:
FDA Issues Final Rule on Data Acceptance from Clinical Investigations for Medical DevicesThe FDA published a final rule on FDA’s standards for accepting data from clinical investigations for medical devices on February 21.
